Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (DE:IKAP)
FRANKFURT:IKAP
RESEARCH TOOLSreports
Aurinia Pharmaceuticals (IKAP) Stock Price & Analysis
1 Followers
IKAP Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.36 - €11.20
Previous Close€5.2
Volume85.00
Average Volume (3M)1.32K
Market Cap
€759.90M
Enterprise Value€546.11M
Total Cash (Recent Filing)$319.91M
Total Debt (Recent Filing)$88.54M
Price to Earnings (P/E)N/A
Beta1.34
Next Earnings
Aug 01, 2024EPS Estimate
<€0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding144,617,762
10 Day Avg. Volume0
30 Day Avg. Volume1,318
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.12
Price to Sales (P/S)3.83
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.85
Enterprise Value/Gross Profit3.38
Enterprise Value/Ebitda-9.64
Forecast
1Y Price Target
€9.55Price Target Upside83.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Aurinia Pharmaceuticals News
PremiumCompany Announcements
Aurinia’s LUPKYNIS Deemed Cost-Effective for Lupus
PremiumCompany Announcements
Aurinia Highlights LUPKYNIS Success in Lupus Treatment
PremiumCompany Announcements
Aurinia Pharmaceuticals to Engage at RBC Healthcare Conference
PremiumCompany Announcements
Aurinia Pharmaceuticals Sees Robust Growth in 2024PremiumCompany Announcements
Aurinia Pharmaceuticals Files SEC Report
Bulls Say, Bears Say
Bulls Say
Financial HealthThe company is expected to generate free cash flow ahead of prior expectations, which could be an attractive milestone for investors.
Market Approval And SentimentLUPKYNIS has been approved in the U.S. and Europe, with high projections for peak sales and royalties.
Product DemandLupkynis sales exceeded estimates, suggesting a favorable launch trend with strong momentum.
Bears Say
Corporate StrategyShares have dropped to a 52-week low following the conclusion of the strategic review without a transaction.
Drug Efficacy And SafetyConcerns remain regarding long-term treatment persistency rates for LUPKYNIS.
Financial PerformanceKey risks include potential revenue growth below expectations, safety issues, and patent challenges that could affect the market.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
16.47% Other Institutional Investors
83.53% Public Companies and
Individual Investors
IKAP FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was €4.36 and its highest was €11.20 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Currently, no data Available
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 76 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on May 02, 2024. The company reported -€0.065 earnings per share for the quarter, beating the consensus estimate of -€0.127 by €0.062.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is <€0.01.
How many shares outstanding does Aurinia Pharmaceuticals have?
Currently, no data Available
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of -€0.065 in its last earnings report, beating expectations of -€0.127. Following the earnings report the stock price went down -0.894%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:IKAP
---
Aurinia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.55 (83.64% Upside)
€9.55 (83.64% Upside)
Blogger Sentiment
Bullish
DE:IKAP Sentiment 92%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.48%
12-Months-Change
Fundamentals
Return on Equity
-16.69%
Trailing 12-Months
Asset Growth
14.36%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
---
IKAP Earnings Call
Q1 2024
0:00 / 0:00
---
IKAP Revenue Breakdown
90.33% Product revenue, net
9.67% License and contract revenue
---
IKAP Stock 12 Month Forecast
Average Price Target
€9.55
▲(83.64% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Teva Pharmaceutical
―
BioMarin Pharmaceutical
―
Incyte
―
Amgen
―
Best Analysts Covering IKAP
1 Year
1 Year Success Rate
14/30 ratings generated profit
1 Year Average Return
+9.94%
assigned a buy rating 16 days ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +9.94% per trade.
---